S&P 500   4,274.51
DOW   33,550.27
QQQ   355.04
The Odds Are High Costco Will Declare a Special Dividend Soon 
Would Buffett Approve of This Growth Strategy? (Ad)
How You Can Reverse Engineer Michael Burry's Latest Buy
Stock market today: Global shares mostly fall over China worries
The Strategic Gold Play You Haven't Heard About (Ad)
Target Will Close 9 Stores Across 4 States Due to Ongoing Crime That's 'Threatening the Safety' of Customers and Employees
Video: Jack in the Box Employee Shoots at Customer Over Alleged Missing Curly Fries, Family Files Lawsuit
The Strategic Gold Play You Haven't Heard About (Ad)
3 Mid-Cap Momentum Plays to Ride Into Q4
I Flew Business Class on 6 Airlines This Year and There Was a Huge Difference Between the Best and the Worst
S&P 500   4,274.51
DOW   33,550.27
QQQ   355.04
The Odds Are High Costco Will Declare a Special Dividend Soon 
Would Buffett Approve of This Growth Strategy? (Ad)
How You Can Reverse Engineer Michael Burry's Latest Buy
Stock market today: Global shares mostly fall over China worries
The Strategic Gold Play You Haven't Heard About (Ad)
Target Will Close 9 Stores Across 4 States Due to Ongoing Crime That's 'Threatening the Safety' of Customers and Employees
Video: Jack in the Box Employee Shoots at Customer Over Alleged Missing Curly Fries, Family Files Lawsuit
The Strategic Gold Play You Haven't Heard About (Ad)
3 Mid-Cap Momentum Plays to Ride Into Q4
I Flew Business Class on 6 Airlines This Year and There Was a Huge Difference Between the Best and the Worst
S&P 500   4,274.51
DOW   33,550.27
QQQ   355.04
The Odds Are High Costco Will Declare a Special Dividend Soon 
Would Buffett Approve of This Growth Strategy? (Ad)
How You Can Reverse Engineer Michael Burry's Latest Buy
Stock market today: Global shares mostly fall over China worries
The Strategic Gold Play You Haven't Heard About (Ad)
Target Will Close 9 Stores Across 4 States Due to Ongoing Crime That's 'Threatening the Safety' of Customers and Employees
Video: Jack in the Box Employee Shoots at Customer Over Alleged Missing Curly Fries, Family Files Lawsuit
The Strategic Gold Play You Haven't Heard About (Ad)
3 Mid-Cap Momentum Plays to Ride Into Q4
I Flew Business Class on 6 Airlines This Year and There Was a Huge Difference Between the Best and the Worst
S&P 500   4,274.51
DOW   33,550.27
QQQ   355.04
The Odds Are High Costco Will Declare a Special Dividend Soon 
Would Buffett Approve of This Growth Strategy? (Ad)
How You Can Reverse Engineer Michael Burry's Latest Buy
Stock market today: Global shares mostly fall over China worries
The Strategic Gold Play You Haven't Heard About (Ad)
Target Will Close 9 Stores Across 4 States Due to Ongoing Crime That's 'Threatening the Safety' of Customers and Employees
Video: Jack in the Box Employee Shoots at Customer Over Alleged Missing Curly Fries, Family Files Lawsuit
The Strategic Gold Play You Haven't Heard About (Ad)
3 Mid-Cap Momentum Plays to Ride Into Q4
I Flew Business Class on 6 Airlines This Year and There Was a Huge Difference Between the Best and the Worst
NASDAQ:LVTX

LAVA Therapeutics (LVTX) Stock Forecast, Price & News

$1.55
+0.05 (+3.34%)
(As of 09/27/2023 ET)
Compare
Today's Range
$1.48
▼
$1.55
50-Day Range
$1.48
▼
$2.00
52-Week Range
$1.37
▼
$7.38
Volume
8,807 shs
Average Volume
12,447 shs
Market Capitalization
N/A
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$6.00
ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media

LAVA Therapeutics MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
287.3% Upside
$6.00 Price Target
Short Interest
Healthy
0.32% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.96mentions of LAVA Therapeutics in the last 14 days
Based on 3 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($1.71) to ($1.56) Per Share

Overall MarketRank™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.37 out of 5 stars

See Top Rated MarketRank™ Stocks Here

LVTX stock logo

About LAVA Therapeutics (NASDAQ:LVTX) Stock

LAVA Therapeutics N.V., a clinical-stage immuno-oncology company, focuses on developing cancer treatments. The company, through its Gammabody platform, develops a portfolio of novel bispecific antibodies to engage and leverage the potency and precision of gamma delta T cells to elicit an anti-tumor immune response and enhance outcomes for cancer patients. Its lead clinical-stage candidates are LAVA-051, which is in Phase 1/2a clinical trial for blood cancers, including chronic lymphocytic leukemia, multiple myeloma, and acute myeloid leukemia; and LAVA-1207 that is in Phase 1/2a clinical trial for metastatic castration-resistant prostate cancer. The company is also developing other Gammabody drug candidates, which include LAVA-1223, which targets the epidermal growth factor receptor (EGFR) for the treatment of selected solid tumors, as well as LAVA-1266 and LAVA-1278, which are preclinical candidates for the treatment of various hematologic malignancies. LAVA Therapeutics N.V. has a research collaboration and license agreement with Janssen Biotech, Inc. for the potential discovery and development of multi-specific antibody products that are directed to a specified target in various fields of use. The company was incorporated in 2016 and is headquartered in Utrecht, the Netherlands.

LVTX Price History

LVTX Stock News Headlines

September 23, 2023 | americanbankingnews.com
Reviewing LAVA Therapeutics (NASDAQ:LVTX) and Dr. Reddy's Laboratories (NYSE:RDY)
August 25, 2023 | bizjournals.com
Lava Therapeutics is latest life sciences company to trim its workforce
September 28, 2023 | Edge On The Street (Ad)
The Strategic Gold Play You Haven't Heard About
Experts recommend adding gold to your portfolio, but in what form? Some savvy investors are now rejecting coins and mining stocks in favor of a unique gold investment alternative. It holds explosive growth potential similar to a junior gold stock -- but with less risk exposure.
August 22, 2023 | finanznachrichten.de
LAVA Therapeutics N.V.: LAVA Therapeutics Provides Business Update and Reports Second Quarter 2023 Financial Results
August 22, 2023 | finance.yahoo.com
LAVA Therapeutics Provides Business Update and Reports Second Quarter 2023 Financial Results
July 6, 2023 | msn.com
LAVA Therapeutics (LVTX) Price Target Decreased by 44.62% to 7.34
June 14, 2023 | finanznachrichten.de
LAVA Therapeutics N.V.: LAVA Therapeutics Provides Updates on Clinical Programs and Extends the Cash Runway
June 14, 2023 | msn.com
Lava Therapeutics shelves hematology drug over competitive concerns
September 28, 2023 | Edge On The Street (Ad)
The Strategic Gold Play You Haven't Heard About
Experts recommend adding gold to your portfolio, but in what form? Some savvy investors are now rejecting coins and mining stocks in favor of a unique gold investment alternative. It holds explosive growth potential similar to a junior gold stock -- but with less risk exposure.
June 12, 2023 | msn.com
HC Wainwright & Co. Reiterates LAVA Therapeutics (LVTX) Buy Recommendation
June 9, 2023 | markets.businessinsider.com
JMP Securities Remains a Buy on LAVA Therapeutics (LVTX)
June 1, 2023 | finance.yahoo.com
LAVA Therapeutics to Participate in the Jefferies Healthcare Conference
May 30, 2023 | finance.yahoo.com
LAVA Announces Annual Meeting of Shareholders
May 30, 2023 | uk.finance.yahoo.com
Is a Beat Likely for Cooper Companies (COO) in Q2 Earnings?
April 17, 2023 | benzinga.com
LAVA Therapeutics Stock (NASDAQ:LVTX), Dividends
April 12, 2023 | markets.businessinsider.com
JMP Securities Sticks to Its Buy Rating for LAVA Therapeutics (LVTX)
April 11, 2023 | finance.yahoo.com
LAVA Therapeutics Provides Business Update and Reports Fourth Quarter and Year-End 2022 Financial Results
March 9, 2023 | finance.yahoo.com
LAVA Therapeutics Announces Appointment of Christy J. Oliger to its Board of Directors
February 16, 2023 | finance.yahoo.com
LAVA Therapeutics Announces Initial Data from the Ongoing Phase 1/2a Clinical Trial of LAVA-1207 in Therapy Refractory mCRPC at the 2023 ASCO GU Symposium
February 9, 2023 | finance.yahoo.com
LAVA Therapeutics to Present at the 2023 SVB Securities Global Biopharma Conference
February 6, 2023 | markets.businessinsider.com
LAVA Therapeutics Appoints Dr. Charles Morris As Chief Medical Officer
January 26, 2023 | seekingalpha.com
LVTX LAVA Therapeutics N.V.
January 23, 2023 | finance.yahoo.com
LAVA Therapeutics to Present LAVA-1207 Clinical Data at the 2023 ASCO GU Symposium
January 6, 2023 | finance.yahoo.com
LAVA Therapeutics Announces Appointment of New Directors to the Board
January 3, 2023 | finance.yahoo.com
LAVA Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference
December 10, 2022 | finance.yahoo.com
LAVA Therapeutics Announces Updated Data from the Phase 1/2a Clinical Trial of LAVA-051 at the 64th American Society of Hematology (ASH) Annual Meeting and Exposition
November 14, 2022 | finance.yahoo.com
Will LAVA Therapeutics N.V. (LVTX) Report Negative Q3 Earnings? What You Should Know
See More Headlines
Receive LVTX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for LAVA Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

LVTX Company Calendar

Last Earnings
8/22/2023
Today
9/28/2023
Next Earnings (Estimated)
11/15/2023
Fiscal Year End
12/31/2023
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:LVTX
CUSIP
N/A
CIK
1840748
Web
www.lavatherapeutics.com
Phone
31-85-016-3100
Fax
N/A
Employees
69
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$6.00
High Stock Price Forecast
$6.00
Low Stock Price Forecast
$6.00
Forecasted Upside/Downside
+287.3%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
2 Analysts

Profitability

EPS (Most Recent Fiscal Year)
($1.54)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-31,910,000.00
Net Margins
-167.49%
Pretax Margin
-166.24%
Return on Equity
-51.14%
Return on Assets
-29.50%

Debt

Debt-to-Equity Ratio
0.02
Current Ratio
5.31
Quick Ratio
5.31

Sales & Book Value

Annual Sales
$19.39 million
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$3.39 per share
Price / Book
0.46

Miscellaneous

Outstanding Shares
N/A
Free Float
N/A
Market Cap
N/A
Optionable
Not Optionable
Beta
-0.39
Beginner's Guide to Pot Stock Investing Cover
Beginner's Guide to Pot Stock Investing

Click the link below and we'll send you MarketBeat's guide to pot stock investing and which pot companies show the most promise.

Get This Free Report

Key Executives

  • Mr. Stephen Allen Hurly M.B.A. (Age 55)
    M.Sc., CEO, Pres & Exec. Director
  • Mr. Fred M. Powell CPA (Age 62)
    Chief Financial Officer
  • Dr. Hans van der Vliet M.D. (Age 49)
    Ph.D., Chief Scientific Officer
  • Ms. Amy Garabedian J.D. (Age 47)
    Gen. Counsel & Corp. Sec.
  • Mr. Wouter van Hunnik
    VP & Head of HR
  • Dr. Ton Adang Ph.D. (Age 62)
    Chief Devel. Officer
  • Dr. Charles Q. Morris M.D. (Age 58)
    MBChB, MRCP (UK), Ph.D., Chief Medical Officer

Key Competitors

View All Competitors

Institutional Ownership

View All Institutional Transactions













LVTX Stock - Frequently Asked Questions

Should I buy or sell LAVA Therapeutics stock right now?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for LAVA Therapeutics in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" LVTX shares.
View LVTX analyst ratings or view top-rated stocks.

What is LAVA Therapeutics' stock price forecast for 2023?

2 Wall Street analysts have issued 1 year target prices for LAVA Therapeutics' stock. Their LVTX share price forecasts range from $6.00 to $6.00. On average, they anticipate the company's share price to reach $6.00 in the next twelve months. This suggests a possible upside of 287.3% from the stock's current price.
View analysts price targets for LVTX or view top-rated stocks among Wall Street analysts.

How have LVTX shares performed in 2023?

LAVA Therapeutics' stock was trading at $3.50 at the beginning of 2023. Since then, LVTX stock has decreased by 55.7% and is now trading at $1.5491.
View the best growth stocks for 2023 here.

Are investors shorting LAVA Therapeutics?

LAVA Therapeutics saw a decrease in short interest in the month of September. As of September 15th, there was short interest totaling 37,900 shares, a decrease of 15.0% from the August 31st total of 44,600 shares. Based on an average daily trading volume, of 34,700 shares, the short-interest ratio is presently 1.1 days. Currently, 0.3% of the shares of the stock are short sold.
View LAVA Therapeutics' Short Interest.

When is LAVA Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, November 15th 2023.
View our LVTX earnings forecast.

How were LAVA Therapeutics' earnings last quarter?

LAVA Therapeutics (NASDAQ:LVTX) released its earnings results on Tuesday, August, 22nd. The company reported ($0.48) earnings per share for the quarter, beating the consensus estimate of ($0.50) by $0.02. The business earned $5.14 million during the quarter, compared to analysts' expectations of $2.50 million. LAVA Therapeutics had a negative net margin of 167.49% and a negative trailing twelve-month return on equity of 51.14%.

When did LAVA Therapeutics IPO?

(LVTX) raised $100 million in an IPO on Thursday, March 25th 2021. The company issued 6,700,000 shares at a price of $14.00-$16.00 per share. J.P. Morgan, Jefferies and SVB Leerink acted as the underwriters for the IPO and Kempen & Co. was co-manager.

What is LAVA Therapeutics' stock symbol?

LAVA Therapeutics trades on the NASDAQ under the ticker symbol "LVTX."

Who are LAVA Therapeutics' major shareholders?

LAVA Therapeutics' stock is owned by many different retail and institutional investors. Top institutional investors include PNC Financial Services Group Inc. (0.00%).

How do I buy shares of LAVA Therapeutics?

Shares of LVTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is LAVA Therapeutics' stock price today?

One share of LVTX stock can currently be purchased for approximately $1.55.

How can I contact LAVA Therapeutics?

The official website for the company is www.lavatherapeutics.com. The company can be reached via phone at 31-85-016-3100 or via email at ir@lavatherapeutics.com.

This page (NASDAQ:LVTX) was last updated on 9/28/2023 by MarketBeat.com Staff

My Account -